EA201300372A1 - ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) - Google Patents
ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS)Info
- Publication number
- EA201300372A1 EA201300372A1 EA201300372A EA201300372A EA201300372A1 EA 201300372 A1 EA201300372 A1 EA 201300372A1 EA 201300372 A EA201300372 A EA 201300372A EA 201300372 A EA201300372 A EA 201300372A EA 201300372 A1 EA201300372 A1 EA 201300372A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutical composition
- options
- therapeutic effect
- increase
- antioxidant
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000003963 antioxidant agent Substances 0.000 title abstract 3
- 230000003078 antioxidant effect Effects 0.000 title abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- AAGFUBJRDPRHIV-UHFFFAOYSA-N 3-ethyl-4-methyl-1H-pyridin-2-one hydrochloride Chemical compound Cl.CCc1c(C)ccnc1O AAGFUBJRDPRHIV-UHFFFAOYSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к области фармацевтической промышленности, медицине. Задачей настоящего изобретения является создание эффективного антиоксидантного фармацевтического состава. Задача решается за счет того, что антиоксидантный фармацевтический состав, содержащий метилэтилпиридинола гидрохлорид, дополнительно содержит минеральные вещества: натрий, калий, кальций, магний, железо, а также содержит изотопы углеродаС и изотопы азотаN. Изобретение описано в четырех вариантах реализации. Техническими результатами изобретения являются увеличение срока годности фармацевтического состава; увеличение лечебного эффекта, а также скорости наступления лечебного эффекта.The invention relates to the field of pharmaceutical industry, medicine. An object of the present invention is to provide an effective antioxidant pharmaceutical composition. The problem is solved due to the fact that the antioxidant pharmaceutical composition containing methyl ethyl pyridinol hydrochloride additionally contains mineral substances: sodium, potassium, calcium, magnesium, iron, and also contains carbon isotopes and nitrogen isotopes N. The invention is described in four embodiments. The technical results of the invention are to increase the shelf life of the pharmaceutical composition; an increase in the therapeutic effect, as well as the rate of onset of the therapeutic effect.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201300372A EA201300372A1 (en) | 2013-04-17 | 2013-04-17 | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) |
| PCT/RU2013/000822 WO2014171854A1 (en) | 2013-04-17 | 2013-09-20 | Antioxidant pharmaceutical composition (variants) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201300372A EA201300372A1 (en) | 2013-04-17 | 2013-04-17 | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201300372A1 true EA201300372A1 (en) | 2014-10-30 |
Family
ID=51731663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201300372A EA201300372A1 (en) | 2013-04-17 | 2013-04-17 | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) |
Country Status (2)
| Country | Link |
|---|---|
| EA (1) | EA201300372A1 (en) |
| WO (1) | WO2014171854A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8591801A1 (en) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | BENZAMID INHIBITORS OF THE P2X7 RECEIVER. |
| RU2455003C1 (en) * | 2011-05-03 | 2012-07-10 | Открытое акционерное общество "Биосинтез" | Formulation and method for preparing infusion dosage form of methylethylpyridinone |
-
2013
- 2013-04-17 EA EA201300372A patent/EA201300372A1/en unknown
- 2013-09-20 WO PCT/RU2013/000822 patent/WO2014171854A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014171854A1 (en) | 2014-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591591A1 (en) | COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors | |
| EA201391285A1 (en) | Derivatives of tetrahydroquinoline, useful as bromodomain inhibitors | |
| EA201592200A1 (en) | DERIVATIVES OF SULFAMOILPYRROLAMIDE AND THEIR APPLICATION AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
| EA201790781A2 (en) | ANTI-VIRUS COMPOUNDS | |
| EA028156B9 (en) | Fused heterocyclic compounds as ion channel modulators | |
| MX2019006878A (en) | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug. | |
| EA201400771A1 (en) | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | |
| EA201691032A1 (en) | IZHOCHROMEN DERIVATIVES AS PHOSFOINOSYTID-3-KINAZ INHIBITORS | |
| GEP201706621B (en) | Benzamides | |
| EA201890331A1 (en) | PYRIDINODICARBOXAMIDES FOR APPLICATION AS BROMODOUM INHIBITORS AS | |
| NZ720651A (en) | Fused heterocyclic compounds as ion channel modulators | |
| EA201692481A1 (en) | COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101 | |
| EA201791807A1 (en) | NEW TRITERPENON WITH C-3 WITH REVERSE AMIDIC DERIVATIVES WITH C-17 AS HIV INHIBITORS | |
| EA201690561A1 (en) | Peptidylnitrile compounds as inhibitors of dipopeptidyl peptidase I | |
| EA201300372A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300378A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300393A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300394A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300376A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300377A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300371A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300392A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300373A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300370A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201200343A1 (en) | PHARMACEUTICAL COMPOSITION, HAVING A NEUROPROTECTIVE, ANTI-AMNESTIC, ANTIOXIDANT, ANTIPIOPOXIC, NEUROMETABOLIC, ANTIVYCHEMICAL ACTIVITY (OPTIONS) |